Ingen Biosciences appoints Research & Development Director

Ingen Biosciences appoints Research & Development Director

Dr. Karine Mignon-Godefroy will head Ingen Biosciences' R&D. Responsibilities include identifying new antigens to develop innovative in vitro diagnostic kits for clinical use.

Chilly-Mazarin near Paris, France, July 8, 2010 - Ingen Biosciences, a developer and marketer of advanced in vitro diagnostic kits for clinical use, today announced that the company has appointed Dr. Karine Mignon-Godefroy as director of research & development.

Dr. Mignon-Godefroy joins Ingen Biosciences just at the point when the company has launched its first proprietary in vitro diagnostic (IVD) kit, as part of its drive to generate new revenue. Ingen Biosciences posted EUR 20 million revenues in 2009, derived mainly from sales of outsourced products. The IVD kits that Ingen Biosciences develops and markets to detect infectious diseases in prosthetic replacements are based on its specialty knowledge in proteomics and expertise in synthesizing new recombinant antigens.

Dr. Mignon-Godefroy will be responsible for identifying clinically relevant recombinant antigens as potential markers for the detection of infectious diseases found in prosthetic replacements, and to develop innovative IVD kits for clinical use.

"We are delighted to have Dr. Karine Mignon-Godefroy join us as we prepare to take the development of products that detect infectious diseases in prosthetic replacements to the next level," says Jean-Pierre Hermet, chairman and CEO of Ingen Biosciences. "Dr Mignon-Godefroy's 15 years' experience in biotechnology, depth of knowledge and skills will be a major contribution to our on-going R&D efforts. Her arrival will also strengthen the team, who have made significant inroads into developing products based on innovative technologies."

Dr. Mignon-Godefroy, (43), joins Ingen Biosciences from the Blood Virus division of Bio-Rad, a manufacturer and distributor of products for a wide range of technologies including proteomics, where she was director of international projects for two years. Before Bio-Rad, she held the post of R&D manager at BMD, a developer of biomedical diagnostics from 2002 - 2008, where she was in charge of developing reagents based on Luminex technology. From 1995 to 2001, Dr. Mignon-Godefroy was group leader at Chemunex (known as AES-Chemunex), a company specializing in detecting microbiological contamination. She received her PhD in Immunology from the University of Pierre and Marie Curie (Paris).

"I am pleased to be joining a strong R&D team that is making key contributions in an area of growing importance," said Dr. Mignon-Godefroy. "I look forward to using my experience, in particular my knowledge in developing diagnostic products based on Luminex technology, to help further the development of clinically relevant in vitro diagnostic kits."

About the Ingen Biosciences Group The Ingen Biosciences Group develops and markets advanced in vitro diagnostic kits for clinical use. Its primary focus is on infectious diseases and immunology, including HLA testing. The company has strong brand recognition in Europe and is growing profitably. Turnover reached EUR 20M in 2009, including out-sourced products. The Group's R&D activities are designed to bring innovative tests to market that are minimally invasive, fast, cost-effective and clinically relevant.

The Group is located in Chilly-Mazarin, near Paris, and employs 65 staff. It is backed by Amundi (formerly known as SGAM AI) and Innoven Partners. Please visit: <http://www.ingen.fr>

For further information, please contact: Andrew Lloyd & Associates Agnes Dalosi / Carol Leslie Tel: +44 1273 675100 [email protected] / c[email protected]

 

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.